Hinge Health, Inc. (HNGE) Earnings

Management highlights

- Core Business Performance & Profitability * Q2 2026 delivered strong top-line and margin expansion: revenue of $213 million (53% YoY growth), operating income of $62 million (more than doubled YoY), operating margin expanded 1000 basis points YoY to 29%, and free cash flow of $100 million (3x YoY growth) with a 47% free cash flow margin. * Operating leverage driven by AI and automation of care delivery, which has improved care team efficiency and expanded gross margin 400 basis points YoY to 87% (including a 100 basis point one-time tariff refund benefit). * LTM calculated billings reached $862 million, up 52% YoY, serving as a strong leading indicator for future revenue growth. - Product & TAM Expansion Strategy * The company's core technology platform is designed for scalable reuse across multiple chronic condition indications, enabling efficient expansion beyond MSK. * Migraine Care has gained rapid client adoption following launch, leveraging the same go-to-market infrastructure and reusable platform components built for MSK. * Management has entered into a definitive agreement to acquire Cylinder Health for $105 million in cash to accelerate entry into GI care, a large unmet need market affecting 1 in 4 U.S. adults that drives $135 billion in annual U.S. medical spend. * GI conditions are highly comorbid with Hinge Health's existing treated conditions (MSK, migraine, pelvic floor), making this a natural extension of the care model, and Cylinder's existing partnerships with top PBMs and national health plans align with Hinge's existing distribution. * The acquisition accelerates Hinge's GI entry timeline by 18-24 months compared to a de novo build, with a modest contribution expected to the 2026 sales season and a full broad rollout targeted for 2027. - Commercial Performance * Active pipeline for the 2027 sales season is ahead of last year's levels, and win rates are at an all-time high YoY. * Enterprise business remains strong, highlighted by a recent large win displacing a competitor at a Fortune 15 company covering 300,000 lives. * Strategic investments in SMB distribution made in late 2025 are paying off, with lives covered growing more than 100% YoY in H1 2026, complementing large enterprise growth. * Multi-product strategy is driving deeper client retention and penetration via the 'land and expand' motion, increasing client stickiness as Hinge addresses more member health needs. * Medicare Advantage (MA) is a growing long-term opportunity, with a recently published study showing Hinge's customized senior offering significantly reduces fall risk in adults 65+, and strong momentum building with existing health plan partners. - Capital Allocation * Capital allocation priorities are: 1) organic product portfolio investment, 2) tuck-in inorganic acquisitions that accelerate growth, 3) return capital to shareholders via share repurchases. * The company ended Q2 with $476 million in cash and equivalents (excluding the planned Cylinder acquisition cash outlay), repurchased 480,000 shares for $26 million in Q2, and the Board of Directors approved a new $300 million share repurchase authorization aligned with the past four quarters of free cash flow generation.

Guidance

- Management raised full-year 2026 guidance driven by better-than-expected durable yield improvements from ongoing operational initiatives: * Full-year 2026 revenue guidance raised to $856-$860 million, representing 46% YoY growth at the midpoint, up from prior guidance. * Full-year 2026 operating income guidance raised to $236-$244 million, representing a 28% operating margin at the midpoint, up from prior guidance of $217-$227 million (27% margin at midpoint). * Full-year 2026 yield is now expected to reach ~4.45%, up from the prior 4.3% forecast, with eligible lives and average selling price tracking in line with prior expectations. * Guidance already includes the expected $7-8 million 2026 revenue contribution from the Cylinder Health acquisition. - Q3 2026 guidance: * Revenue of $223-$225 million, representing 45% YoY growth at the midpoint. * Operating income of $61-$63 million, representing a 28% operating margin at the midpoint. - 2026 diluted weighted average diluted shares outstanding are expected to end the year at 85-87 million, with the increase from Q2 driven by conversion of remaining preferred shares, and already reflecting year-to-date buyback activity. - Long-term yield guidance indicates management sees a clear path to expanding current yield from ~4.45% to 12-15% over time, supported by new product offerings (migraine, GI) that add incremental engagement opportunities.

Segment performance

Hinge Health reports financial performance across its core and new product segments: 1) Core Musculoskeletal (MSK) Care: This is the company's foundational segment, contributing ~91% of current enrollment yield. Q2 2026 revenue from the core MSK business drove the majority of the company's total $213 million Q2 revenue, with strong yield improvements from clinically targeted enrollment campaigns, member referrals, and renewals. 2) Migraine Care: Launched in Q1 2026, this segment already has over 450 clients signed covering more than 5 million lives. Early enrollment and engagement metrics meet management expectations, and it is on track to contribute 10-20 basis points of incremental yield to the full-year 2027 results. 3) Gastrointestinal (GI) Care (via planned acquisition of Cylinder Health): Cylinder Health currently has nearly 100 clients across 2 million lives, and is expected to contribute $7-8 million in revenue to Hinge Health in the remaining four months of 2026. Revenue contribution will increase meaningfully in 2027, with significant scaling expected starting in 2028 after a full year of sales integration.

Risks & headwinds

- Forward-looking statements (including guidance, product expansion timelines, and revenue contributions from new acquisitions) are subject to inherent risks and uncertainties that could cause actual results to differ materially, as detailed in the company's SEC filings (Form 10-K 2025, upcoming Form 10-Q for Q2 2026). * Product integration of Cylinder Health requires 9-12 months of work to unify into Hinge's core platform, and there is execution risk related to completing integration on the expected timeline and achieving projected margin improvements. * Sales pipeline conversion is concentrated in the second half of the year (70%+ of employer benefits decisions are made in late Q3 to mid Q4 for January launch), so there is inherent timing risk to 2027 revenue growth if conversion does not meet expectations. * Increasing competitive activity in the digital musculoskeletal and chronic care market could pressure win rates and pricing, though management notes Hinge's scale, proven results, and product quality have driven improving win rates to date.

Analyst Q&A

• Q: How replicable is Hinge's core care model for GI, and is GI expected to require more in-person/live care than existing offerings? /

  A: GI has massive unmet need, and demand is growing as GI side effects from GLP-1s rise in prevalence. Cylinder's business model is already very analogous to Hinge's: it serves the same customers, uses the same go-to-market motion, and shares the same key PBM and health plan partners. Similar to MSK and migraine, Hinge's GI offering will be AI/tech driven at its core, with personalized nutrition guidance and trigger identification, paired with on-demand access to human specialist support when needed. The acquisition gives Hinge an 18-24 month head start compared to building GI internally.

• Q: What is Hinge's appetite for additional M&A after the Cylinder acquisition, and how did this deal come together? /

  A: Hinge has a default strategy of building new products organically, as it did with migraine, but will pursue M&A when it accelerates the company's timeline and meets return thresholds. Hinge had followed Cylinder for a long time, got consistent client feedback that GI was a top unmet need, and moved into earnest negotiations several months ago. Hinge receives multiple inbound acquisition opportunities monthly, maintains a high bar for deals, and has the strong balance sheet and free cash flow to pursue attractive strategic opportunities that fit the company's multi-condition expansion strategy.

• Q: What explains the higher-than-expected full-year 2026 yield of 4.45%, and is yield improvement broad-based across existing and new clients? /

  A: Yield improvements are broad-based across both existing legacy clients and new clients, driven by multiple mutually reinforcing factors: targeted enrollment campaigns, member-to-member referrals, returning members seeking additional care, and product portfolio expansion. Currently, ~91% of yield still comes from core MSK, but new indications like migraine and GI will add incremental yield over time. Management sees a long multi-year path to continued yield expansion, as new products open up additional engagement opportunities for members.

• Q: What is Hinge's competitive positioning, how do you respond to claims of high win rates from key competitors? /

  A: Management notes Hinge's win rate is at an all-time high, and the company has recently won multiple large accounts from competitors. As a public company, Hinge is transparent about its data, while private competitors can publish unvetted metrics. Hinge is 3-4x larger than its closest competitor, and a competitor claiming 70%+ win rate for five years while remaining far smaller than Hinge calls that claim into question. Hinge's strong product experience, proven clinical results, and scale have driven improving competitive positioning.